Epkinly (epcoritamab-bysp) / Genmab, AbbVie  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Epkinly (epcoritamab-bysp) / Genmab, AbbVie
ACTRN12625000965404: ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation

Not yet recruiting
3
116
 
Australasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group, University of Cologne
Cancer, Richter Transformation, Chronic Lymphocytic Leukemia (CLL)
 
 
GCT3013-05 Sub, NCT07226752: A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

Active, not recruiting
3
72
RoW
Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, Investigator's Choice Chemotherapy
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
10/25
06/28
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1095
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
11/37
11/37
EPCORE DLBCL-4, NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/28
01/28
EPCORE DLBCL-1, NCT04628494 / 2020-003016-27: A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Hourglass Apr 2024 - Dec 2024 : Data for 3L+ DLBCL
Active, not recruiting
3
484
Europe, Canada, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, Investigator's Choice Chemotherapy, BR or R-GemOx
Genmab, AbbVie
Diffuse Large B-cell Lymphoma
10/25
04/28
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
06/27
12/29
EPCORE FL-1, NCT05409066 / 2021-000169-34: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Active, not recruiting
3
549
Europe, Canada, Japan, US, RoW
Epcoritamab, Rituximab, Lenalidomide
Genmab, AbbVie
Follicular Lymphoma (FL)
12/29
12/29

Download Options